A first generation cephalosporin, cephalexin exhibits activity against the bacteria usually covered by this class. Cephalosporins are bactericidal against susceptible bacteria and act by inhibiting mucopeptide synthesis in the cell wall resulting in a defective barrier and an osmotically unstable spheroplast. The exact mechanism for this effect has not been definitively determined, but beta-lactam antibiotics have been shown to bind to several enzymes (carboxypeptidases, transpeptidases, endopeptidases) within the bacterial cytoplasmic membrane that are involved with cell wall synthesis. The different affinities that various beta-lactam antibiotics have for these enzymes (also known as penicillin-binding proteins; PBPs) help explain the differences in spectrums of activity of these drugs that are not explained by the influence of beta-lactamases. Like other beta-lactam antibiotics, cephalosporins are generally considered to be more effective against actively growing bacteria. While there may be differences in MIC’s for individual first generation cephalosporins, their spectrums of activity are quite similar. They possess generally excellent coverage against most gram-positive pathogens and variable to poor coverage against most gramnegative pathogens. These drugs are very active _in vitro_ against groups _A_ beta-hemolytic and B Streptococci, non-enterococcal group D Streptococci ( _S. bovis_ ), _Staphylococcus intermedius_ and _aureas_, _Proteus mirabilis_ and some strains of _E. coli_, _Klebsiella_ spp., Actinobacillus, Pasturella, _Haemophilus_ _equigenitalis_, Shigella and Salmonella. With the exception of _Bacteroides_ _fragilis_, most anaerobes are very susceptible to the first generation agents. Most species of Corynebacteria are susceptible, but _C. equi_ (Rhodococcus) is usually resistant. Strains of _Staphylococcus epidermidis_ are usually sensitive to the parenterally administered 1st generation drugs, but may have variable suscept
There are no approved cephalexin products for veterinary use in the USA. However, it has been used clinically in dogs, cats, horses, rabbits, ferrets, and birds, particularly for susceptible Staphylococcal infections.
劑量數字暫停提供:VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容,DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源;計算機可手動輸入劑量換算。
腎功能調整:Reduce dose frequency to q12-24h in renal impairment
腎功能調整:Reduce dose frequency to q12-24h in renal impairment
確認 Cephalexin 或 Cefalexin 拼法、active parent、monohydrate 或其他鹽、效價基準、商品、強度、劑型、刻痕、容器、修訂版本與法域 確認物種、體重、年齡、感染部位與深度、檢體、細胞學、病原、菌株、培養感受性方法與可適用判讀標準 區分經驗性與目標性治療,先評估局部治療、underlying cause、地區抗藥性、替代方案、抗菌藥管理及法規 核對頭孢菌素、青黴素與其他 β 內醯胺過敏、腎肝功能、水合、生殖狀態、誤食風險及所有藥品與補充品 建立個別化的臨床反應、過敏、腸胃、腎臟、神經、血液、二重感染、檢驗干擾與停換藥監測計畫
DRUGAPI 劑量審查引用的獸醫官方標示(各標示只適用於其產品、物種與法域,不可互換)
依出現頻率分組;嚴重副作用獨立列出,臨床上需立即辨識。
64-70 minutes